
The past week has brought a series of developments across femtech, from a new wearable designed to support hormone-free contraception to AI-powered menopause care and the introduction of an advanced breast cancer risk assessment test in the UK.
Here are four launches and developments shaping the women’s health technology landscape.
Natural Cycles launches smart ring for digital contraception
Natural Cycles has launched its first smart ring, offering users another wearable option for monitoring fertility and supporting hormone-free contraception.
The NC° Ring measures overnight temperature and synchronises with the Natural Cycles app, which combines the data with menstrual cycle information to provide users with a daily fertility status.
Available to order in Europe, Canada and Australia from 17 November, the ring weighs as little as 1.9g, measures 5.8mm wide and offers up to 14 days of battery life.
It has been designed without a raised sensor bump and uses temperature and movement sensors that operate without the optical lights commonly found in smart rings.
The device is being offered at no additional cost with a new annual Natural Cycles subscription until 31 December 2026.
The company says around 80 per cent of its active users already use a wearable to measure their temperature, reflecting growing demand for integrated fertility tracking.
Natural Cycles’ contraceptive app is 93 per cent effective with typical use, according to the company.
Longevitix introduces AI-powered women’s health platform
Longevitix has launched a new women’s health extension to its AI-powered clinical platform, designed to help healthcare professionals deliver more personalised care during perimenopause and menopause.
Announced on 13 November, the extension brings together medical records, laboratory results, imaging, wearable data and patient-reported symptoms to give clinicians a more comprehensive picture of a patient’s health.
The platform covers seven women’s health domains, including hormones and menstrual cycles, gynaecological and reproductive health, cancer screening, sexual health, pelvic and urinary health, hair and skin, and bone and muscle health.
It also integrates with wearable technologies and services including Oura, Apple Health and Whoop, allowing clinicians to consider information such as sleep quality, overnight temperature and heart rate alongside other clinical data.
Patients can record symptoms through daily journals, while the platform provides personalised reports and care plans.
Longevitix says its technology is designed to help clinicians identify connections between symptoms and health changes that might otherwise be considered separately. Treatment decisions remain under the control of healthcare professionals.
EDX Medical brings AI-powered breast cancer test to UK
UK diagnostics company EDX Medical has announced the launch of an AI-powered breast cancer test in the UK through a partnership with US precision medicine company Caris Life Sciences.
The Caris MI Clarity test assesses both short and long-term distant breast cancer recurrence risk, including the possibility of recurrence up to 15 years after diagnosis.
Designed for postmenopausal patients with early-stage, hormone receptor-positive, HER2-negative, node-negative breast cancer, the test uses an AI model combining tumour pathology images with clinical and molecular data.
It is intended to provide clinicians with a more comprehensive assessment of recurrence risk at the point of initial diagnosis, helping inform treatment planning.
The launch, announced on 10 November, expands access to precision diagnostics in the UK and addresses a significant challenge in breast cancer care: understanding the longer-term risk of recurrence when making treatment decisions.
MHRA launches programme to address women’s health evidence gaps
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new Women’s Health Programme aimed at addressing longstanding gaps in clinical evidence and supporting innovation in women’s health.
Announced on 16 November, the programme will explore how the risks and benefits of medicines and medical devices may differ for women, bringing together patients, researchers, healthcare professionals and industry.
The initiative follows an analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023, which found that pregnant women were represented in just 1.1 per cent of trials and breastfeeding women in 0.6%.
The regulator hopes to improve the evidence available to support the development of medicines and medical technologies that better reflect women’s needs.
It also aims to work with innovators earlier in the development process, helping promising products reach patients while maintaining safety and quality standards.
The programme represents an important regulatory development for the UK’s femtech sector, which the MHRA estimates generates nearly £300m in annual turnover.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.








